Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PReCedeNT: PRRT vs PRRT plus CAPE-TEM in GEP-NETs
NCT07185672Phase 3Recruiting
- Sponsor
- Tata Memorial Hospital
- Start
- Aug 2019
- Primary completion
- Aug 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, temozolomide in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Tata Memorial Hospital. Started Aug 2019; status: recruiting.
02
Drugs
capecitabinetemozolomide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT07185672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185672.